Hans-Christian Kolberg, MD: Biosimilars and Patient Access
August 5th 2019Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the impact that biosimilars have made on patient access to therapy.
Hans-Christian Kolberg, MD: Real-World Evidence and Biosimilar Trastuzumab
July 22nd 2019Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the role of real-world evidence for biosimilar trastuzumab.
Ali McBride, PharmD, MS, BCPS: Pharmacists' Concerns About Biosimilar Implementation
July 3rd 2019Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses areas where pharmacists still have questions about biosimilars and their implementation.
Elaine Blais, JD: Trends in Patent Settlements
July 1st 2019Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses whether a recent spate of patent settlements related to biosimilars reflects a shift away from lengthy Biologics Price Competition and Innovation Act (BPCIA) litigation.
Hans-Christian Kolberg, MD: The Importance of Reporting Data on Biosimilar Trastuzumab
June 6th 2019Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.
Kalveer Flora, MPharm: Patient Response to Switching to Biosimilar Adalimumab
June 3rd 2019Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses how patients have reacted to being switched to biosimilar adalimumab and how they have been supported in the switching process.